Market and Business Analysis of Tissue Engineered Blood Vessels
PúblicoConteúdo disponível para baixar
open in viewerCardiovascular disease is the number one leading cause of death in the United States. Myocardial infarctions are caused by cardiovascular disease and more specifically, by the blocking of a main artery in the heart. A team of students at WPI designed a device and method for producing tissue engineered blood vessels (TEBVs), which are proposed to be a new and effective treatment for coronary artery bypass surgery. The purpose of this study was to decide whether TEBVs were a worthwhile commercial venture. Currently, the method to produce the TEBVs is still being altered and the grafts are still in the early development stages. It was determined, however, that TEBVs are a worthwhile venture to invest in due to the high demand in the cardiovascular disease treatment market.
- This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.
- Creator
- Publisher
- Identifier
- E-project-042611-122827
- Advisor
- Year
- 2011
- Date created
- 2011-04-26
- Resource type
- Major
- Rights statement
- Última modificação
- 2021-02-02
Relações
- Em Collection:
Itens
Itens
Miniatura | Título | Acesso | Embargo Release Date | Ações |
---|---|---|---|---|
BrentEvansen_MQP_MarketAnalysisofTEBVs.pdf | Público | Baixar |
Permanent link to this page: https://digital.wpi.edu/show/3b591b13v